Abstract: RNA encoding immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
Abstract: The application discloses method of immunising against Neisseria meningitidis infection comprising the steps of a) immunising a human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a Neisseria meningitidis conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N.
Abstract: Methods for the enzymatic modification of saponins, products made thereby, uses of said products and also to other associated aspects. The saponins may be extracts of Quillaja species, such as extracts of Quillaja saponaria Molina.
Type:
Application
Filed:
December 8, 2021
Publication date:
January 25, 2024
Applicant:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Murray BROWN, Edward CHAPMAN, Andrew COLLIS, Douglas FUERST, Joseph HOSFORD, Christopher MACDERMAID, James MORRISON
Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
Type:
Application
Filed:
September 5, 2023
Publication date:
January 25, 2024
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is 0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.
Type:
Application
Filed:
July 17, 2023
Publication date:
January 25, 2024
Applicant:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Ahmad Taimour BAIG, Juan Jose DIAZ GARCIA, Chad Austin FARRENBURG, Kent Raymond MYERS, Jeri Kay SANDVICK, Jeb Yeatts VANDENBURG
Abstract: The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.
Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunising subjects against various diseases.
Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
Type:
Grant
Filed:
August 6, 2021
Date of Patent:
January 16, 2024
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
Type:
Grant
Filed:
May 31, 2022
Date of Patent:
January 16, 2024
Assignees:
CUREVAC SE, GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Nicole Roth, Diego Chaves Moreno, Hans Wolfgang Große, Dominik Vahrenhorst, Susanne Rauch
Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).
Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
Type:
Grant
Filed:
December 13, 2022
Date of Patent:
January 9, 2024
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
Abstract: An adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein each transgene encodes an RSV antigenic protein or a fragment thereof.
Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
Type:
Grant
Filed:
December 13, 2022
Date of Patent:
January 2, 2024
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
Abstract: Provided are compounds and pharmaceutical compositions and uses thereof for inhibiting Nav1.8 voltage-gated sodium ion channels and treating Nav1.8 mediated diseases, such as pain and pain-associated diseases, and cardiovascular diseases.
Type:
Application
Filed:
June 7, 2023
Publication date:
December 28, 2023
Applicant:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors:
Jie GUANG, Jay M. MATTHEWS, Alan T. PRICE, Jared Troy SPLETSTOSER
Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, the present invention relates to sized Streptococcus pneumoniae serotype 6A capsular polysaccharides, in particular Streptococcus pneumoniae serotype 6A capsular polysaccharides having the average size (e.g. Mw) of the Streptococcus pneumoniae serotype 6A capsular polysaccharide is between 100-1000 kDa, suitably conjugated to a carrier protein.
Type:
Grant
Filed:
October 19, 2016
Date of Patent:
December 19, 2023
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Elisabeth Marie Monique Bertaud, Ralph Leon Biemans, Nicolas Jean Benoit Moniotte, Laurent Bernard Jean Strodiot
Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 ?g and 100 ?g. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 ?g and 100 ?g of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.